Overview

• Researchers surveyed 591 women about six years after diagnosis and found 47% opted to continue endocrine therapy beyond five years.
• Continuation rates reached 62% among stage 2 patients compared with 39% for stage 1 patients.
• Younger survivors and those who previously received chemotherapy were more likely to commit to extended treatment.
• Oncologists’ recommendations and patients’ fear of recurrence emerged as the strongest influences on therapy extension decisions.
• Primary care physicians’ involvement in treatment discussions significantly increased the likelihood of patients extending therapy.